KYVERNA THERAPEUTICS, INC. COMMON STOCK

NASDAQ: KYTX (Kyverna Therapeutics, Inc.)

Last update: 10 hours ago

7.92

-0.23 (-2.82%)

Previous Close 8.15
Open 8.15
Volume 592,110
Avg. Volume (3M) 938,201
Market Cap 481,498,080
Price / Book 2.50
52 Weeks Range
2.52 (-68%) — 13.67 (72%)
Earnings Date 12 Aug 2026
Diluted EPS (TTM) -3.24
Total Debt/Equity (MRQ) 3.10%
Current Ratio (MRQ) 7.44
Operating Cash Flow (TTM) -133.64 M
Levered Free Cash Flow (TTM) -80.19 M
Return on Assets (TTM) -31.08%
Return on Equity (TTM) -49.72%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Kyverna Therapeutics, Inc. Mixed Bullish

AIStockmoo Score

0.5
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
KYTX 481 M - - 2.50
ASND 15 B - 24.98 25.41
LEGN 6 B - - 7.48
CNTA 6 B - - 12.62
IMAB 534 M - - 2.42
QTTB 218 M - 4.54 4.62

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 12.04%
% Held by Institutions 68.57%

Ownership

Name Date Shares Held
Vida Ventures Advisors, Llc 30 Sep 2025 4,523,924
Insight Holdings Group, Llc 31 Mar 2026 989,054

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria